Illumina chief legal officer sells shares, stock trades near 52-week high

Illumina sees insider selling from its chief legal officer while NASDAQ-listed shares continue to trade close to a 52-week high after a strong year in biotech sequencing.

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 11:20.

Illumina Inc. (US4523271090) has reported fresh insider dealing by its chief legal officer. The NASDAQ-listed sequencing specialist sees the move against a backdrop of shares trading close to a 52-week high in the U.S. life sciences segment, according to Investing.com and MarketBeat.

What the Form 4 shows

According to a recent Form 4 filing summarized by StockTitan, Illumina's Chief Legal Officer Scott M. Davies sold 615 shares of common stock in an open-market transaction. The shares were sold at a price of 180 dollars each, implying proceeds of 110,700 dollars per the SEC-based summary and Investing.com report.

Following the sale, Davies still directly owns 20,953 Illumina shares, so the transaction represents only a small fraction of his reported stake. The filing lists transaction code "S" for a non-derivative equity sale and shows no concurrent derivatives activity, underscoring that this was a straightforward stock disposal rather than an options-related trade.

How the shares trade on NASDAQ

Illumina shares trade on NASDAQ under the ticker ILMN and have delivered a marked recovery over the past year. Investing.com notes that the stock has returned around 80 percent over twelve months and is trading near its 52-week high, despite a recent pullback that left the price roughly at 160 dollars at the time of the analyst snapshot.

Additional context from MarketBeat data shows that Illumina shares opened at 177.65 dollars on the most recent Friday session. The life sciences group carries a market capitalization of roughly 26.9 billion dollars, a price-earnings ratio of about 32, and a beta near 1.5, placing it among the larger, growth-oriented names in the genomics tools peer group.

The analyst and consensus picture

On the analyst side, Guggenheim has recently raised its price target for Illumina shares to 180 dollars, up from 170 dollars, while reiterating a Buy rating. The move followed discussions with company financial leadership on clinical market growth prospects and reflects a constructive stance on Illumina's earnings trajectory in sequencing for healthcare.

Separate data aggregated by MarketBeat indicates that Illumina still carries an average rating of Hold across covering houses, with a consensus target near 143.56 dollars. That gap between the current price region and the average target illustrates a cautious overall stance from the broader analyst community, even as selected firms like Guggenheim remain more optimistic.

Recent earnings and guidance

Illumina last reported quarterly results on April 30, 2026, beating earnings expectations. The company delivered earnings per share of 1.15 dollars compared with consensus estimates of 1.05 dollars, a positive surprise of 0.10 dollars per share that underlined solid execution in the period.

Revenue for the quarter grew 4.8 percent year-over-year, reflecting steady demand for sequencing instruments and consumables across research and clinical customers. Illumina has set its full-year 2026 guidance in a range of 5.15 to 5.30 dollars in EPS, while analysts project roughly 5.21 dollars per share, placing expectations around the middle of management's corridor.

Operational developments in sequencing

Illumina has paired its financial development with several operational announcements in recent months. According to an Investing.com company update, the group launched the StrataMap Spatial Solution, a new sequencing-based platform designed for spatial transcriptomics research with a 7.5 square centimeter capture area and whole-transcriptome profiling at single-cell resolution.

The company also introduced a whole-genome sequencing solution targeted at molecular residual disease research, currently in early access with selected clinical partners and planned for broader global availability next year. In oncology, Illumina entered a collaboration with Integrated DNA Technologies to integrate IDT's library preparation solutions with its DRAGEN secondary analysis platform, aiming to streamline workflows for cancer research laboratories.

Corporate governance and board changes

Corporate governance has also evolved, with Illumina appointing Daniel M. Skovronsky, a senior executive from Eli Lilly, to its board of directors. The appointment adds big-pharma clinical development experience to Illumina's boardroom and underscores the company's focus on expanding its footprint in clinical genomics rather than purely research sequencing.

Such board additions are closely watched by sector peers like Thermo Fisher Scientific and Agilent Technologies, as they may signal shifts in strategic emphasis toward regulated diagnostic applications. For investors, the presence of a seasoned pharmaceutical executive can be read as support for Illumina's ambition to deepen ties with drug developers and healthcare systems.

What the company sells in genomics

Illumina generates revenue primarily by selling next-generation sequencing platforms, consumables and associated software used to analyze genetic variation and function. Core offerings include benchtop and production-scale sequencers, flow cells and reagents, plus bioinformatics solutions such as the DRAGEN platform to interpret genome, exome and transcriptome data for research and clinical customers.

Where the stock trades today

Illumina shares (US4523271090) trade on NASDAQ under the ticker ILMN and recently changed hands around 177.65 dollars in U.S. trading on 2026-06-25, 16:00 Eastern, based on MarketBeat quote data. That level places the stock close to its 52-week high of 182.84 dollars, with a 52-week low reported near 88 dollars, underlining the marked recovery over the past year.

Illumina in brief

• Company: Illumina Inc.
• ISIN: US4523271090
• WKN: 927079
• Ticker: ILMN
• Trading venue: NASDAQ
• Price (as of 2026-06-25, 16:00): 177.65 USD
• Market cap: 26.88 billion USD (as of 2026-06-25)
• Sector / industry: Life Sciences Tools & Services / Biotechnology equipment
• Index membership: S&P 500
• Next earnings date: 2026-07-30

This article is for informational purposes only and does not constitute investment advice, a buy or sell recommendation, or any form of financial promotion. All data are based on publicly available sources believed to be reliable, but accuracy and completeness are not guaranteed. Investors should conduct their own research or consult a qualified advisor before making investment decisions.